Boston Scientific slashes 2026 forecast as cyberattack hits sales (BSX:NYSE)
Boston Scientific reported Q3 Non-GAAP EPS of $0.73, beating estimates by $0.01, with revenue of $5.14B, up 1.4% year-over-year. The company reduced its 2026 guidance, citing a cyberattack's impact on sales, with adjusted EPS forecasted at $3.16–$3.18, below the consensus of $3.23.
How this was made
The 30-second read
Why it matters
The guidance shortfall is material for traders; the EPS beat is modest and may not offset the outlook downgrade.
Market read
Guidance miss is a primary catalyst for BSX price movement; sector peers may be watched for similar impacts.
What to watch
Potential cost‑saving measures or new product pipelines not disclosed yet.
Background
Boston Scientific disclosed Q3 results and FY2026 guidance amid a reported cyber‑attack affecting sales.
Ticker impact
Boston Scientific reported Q3 non‑GAAP EPS beat and lowered FY2026 adjusted EPS guidance to $3.16‑$3.18, below consensus.
likely downside as investors price in lower earnings outlook
Guidance below consensus for a large‑cap medtech firm typically triggers sell‑off.
Market effects
Medtech sector may face broader pressure if guidance miss signals demand slowdown.
U.S. equities could see modest pullback in healthcare indexes.
Limited to investors tracking U.S. medtech earnings.
Counterpoint
If the cyber‑attack impact is temporary, the guidance cut may be over‑reacted to.
Key entities
- companyBoston Scientific
Medical device manufacturer (ticker BSX).
